Equities research analysts at Canaccord Genuity started coverage on shares of Heska Corporation (NASDAQ:HSKA) in a research note issued on Thursday. The firm set a “buy” rating and a $115.00 price target on the medical research company’s stock. Canaccord Genuity’s price target suggests a potential upside of 19.42% from the company’s current price.

Several other equities research analysts have also weighed in on HSKA. BidaskClub lowered Heska Corporation from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. B. Riley reissued a “neutral” rating and issued a $85.00 price objective on shares of Heska Corporation in a report on Friday, July 28th. Aegis lifted their price objective on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a report on Tuesday, August 1st. Benchmark Co. lifted their price objective on Heska Corporation from $106.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research raised Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price objective for the company in a report on Friday, August 4th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Heska Corporation has an average rating of “Hold” and an average target price of $106.83.

Shares of Heska Corporation (NASDAQ:HSKA) opened at 96.12 on Thursday. The stock has a 50 day moving average of $94.65 and a 200-day moving average of $98.32. Heska Corporation has a 12 month low of $46.51 and a 12 month high of $115.00. The company has a market cap of $694.56 million, a PE ratio of 48.99 and a beta of 0.84.

Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The company had revenue of $34.30 million during the quarter, compared to analyst estimates of $33.35 million. During the same quarter last year, the firm posted $0.35 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. Equities analysts forecast that Heska Corporation will post $2.04 earnings per share for the current year.

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/heska-corporation-hska-coverage-initiated-at-canaccord-genuity/1615073.html.

In other Heska Corporation news, EVP Nancy Wisnewski sold 825 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the completion of the transaction, the executive vice president now owns 38,114 shares in the company, valued at approximately $3,895,631.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO John Mcmahon sold 2,608 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the transaction, the chief financial officer now owns 193 shares of the company’s stock, valued at approximately $19,525.81. The disclosure for this sale can be found here. 14.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of HSKA. Vanguard Group Inc. boosted its stake in Heska Corporation by 47.0% in the 1st quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after purchasing an additional 112,115 shares during the period. Dimensional Fund Advisors LP boosted its stake in Heska Corporation by 115.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock worth $12,266,000 after purchasing an additional 64,418 shares during the period. Geneva Advisors LLC boosted its stake in Heska Corporation by 565.4% in the 2nd quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock worth $7,706,000 after purchasing an additional 64,153 shares during the period. Fred Alger Management Inc. boosted its stake in Heska Corporation by 133.8% in the 2nd quarter. Fred Alger Management Inc. now owns 97,229 shares of the medical research company’s stock worth $9,924,000 after purchasing an additional 55,647 shares during the period. Finally, Principal Financial Group Inc. bought a new position in Heska Corporation in the 1st quarter worth about $5,234,000. Institutional investors and hedge funds own 81.36% of the company’s stock.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.